



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, D.C. 20231, ON 11 FEBRUARY 2000

ATTORNEY FOR APPLICANT

TC 1600 MAIL ROOM

P50464-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re:

Jackson et al.

11 February 2000

Serial No.:

09/142,983

Group Art Unit No. 1614

Filing Date:

17 September 1998

Examiner: T. Criares

For:

PLA₂ Inhibitors for Angiogenesis

Assistant Commissioner of Patents Washington, D.C. 20231

RESPONSE

Sir:

In response to the Examiner's office action of 11 August 1999 in the above noted application, please enter the following remarks and amendments into the record. Also enclosed herewith is a petition for a three (3) month extension of the shortened statutory period set by the Examiner and authorization to charge the required fee to the indicated deposit account.

In the Specification:

Page 12, line 32, please delete the word "a".

In the Claims:

Please amend the following claims:

Claim 1. (amended) A method of treating a chronic disease in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis, with an effective amount of a compound which inhibits the production, transcription, translation or activity of 14 kDa PLA₂ and wherein the compounds were

invented after the priority date of March 26, 1996.

Claim 5 (amended) A method of treating a chronic disease in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate

02/17/2000 HLE111

00000011 192570 09142983

01 FC:117

870.00 CH

03/15/2000 KHARMUN 00000003 1 Sale Ref: 00000003 DAH: 1925/0 01 FC:102